ID4 Pharma
Curated by SignalCompany developing treatments for multiple myeloma through its medchem/biology-based drug discovery platform
Overview
ID4 Pharma (short for Intelligent Drug Design Discovery Development) is engaged in the development of novel treatments for Multiple Myeloma (MM) through its Medicinal Chemistry/Biology Drug Discovery Platform which leverages the power of big data and machine learning techniques. The company owns the sequestosome-1/p62-targeted small molecule Multiple Myeloma treatment and claims that it has a high anti-MM efficacy, toxicological safety, no drug resistance, and a good PK bio-availability when compared to the currently available treatments in the market. The company has received a $2.3 million NIH federal 'fast track' grant to complete its FDA IND-enabling preclinical R&D studies and is also looking for partnerships with pharma/biotech companies, investors and venture capitalists.
Key facts
- Founded
- 2015
- Headquarters
- Bridgeville, United States
- Stage
- Sign up to view
- Industry
- Life Sciences Technology
Business model
- 5 products and services
- Sign up to view
Contact
- Primary office
- Sign up to view
- Sign up to view
- Phone
- Sign up to view